AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity

International Journal of Hematology

Volumn 88, Issue 4, 2008, Pages 381-386

  Lindner, L H ^a   Ostermann, H ^a   Hiddemann, W ^a   Kiani, A ^b   Wurfel M ^b   Illmer, T ^b   Karsch, C ^b   Platzbecker, U ^b   Ehninger, G ^b   Schleyer, E ^b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Carl von Basedow Hospital   (Germany)

Author keywords

Cytarabine; Pharmacokinetics; Renal insufficiency; Uracil arabinoside

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; MITOXANTRONE; URACIL ARABINOSIDE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEUROTOXICITY; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; HALF LIFE TIME; MIDDLE AGED; TOXICITY AND INTOXICATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLURACIL; CYTARABINE; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES;

EID: 64249131662     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0171-7     Document Type: Article

References (41)

1. RW Talley VK Vaitkevicius 1963 Megaloblastosis produced by cytosine antagonist 1-ß-d-arabinofuranosylcytosine Blood 21 352 62
2. W Hiddemann 1991 Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens Ann Hematol 62 119 28 10.1007/BF01702925
3. RL Capizzi 1996 Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside Invest New Drugs 14 249 56 10.1007/BF00194527
4. W Hiddemann E Schleyer M Unterhalt M Zuhlsdorf C Rolf C Reuter 1992 Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells Leukemia 6 1273 80
5. W Hiddemann E Schleyer M Unterhalt W Kern T Buchner 1996 Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells Ther Drug Monit 18 341 9 10.1097/00007691-199608000- 00005
6. W Kern EH Estey 2006 High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials Cancer 107 116 24 10.1002/cncr.21543
7. TL Hwang WK Yung EH Estey WS Fields 1985 Central nervous system toxicity with high-dose Ara-C Neurology 35 1475 9
8. HM Lazarus RH Herzig GP Herzig GL Phillips U Roessmann DJ Fishman 1981 Central nervous system toxicity of high-dose systemic cytosine arabinoside Cancer 48 2577 82 10.1002/1097-0142(19811215)48:12<2577::AID- CNCR2820481207>3.0.CO;2-Z
9. RH Herzig HM Lazarus GP Herzig PF Coccia SN Wolff 1985 Central nervous system toxicity with high-dose cytosine arabinoside Semin Oncol 12 233 6
10. RH Herzig GP Herzig SN Wolff JD Hines JW Fay GL Phillips 1987 Central nervous system effects of high-dose cytosine arabinoside Semin Oncol 14 21 4
11. S Nand HL Messmore Jr R Patel SG Fisher RI Fisher 1986 Neurotoxicity associated with systemic high-dose cytosine arabinoside J Clin Oncol 4 571 5
12. EH Rubin JW Andersen DT Berg CA Schiffer RJ Mayer RM Stone 1992 Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia J Clin Oncol 10 948 53
13. L Grossman MA Baker DM Sutton JH Deck 1983 Central nervous system toxicity of high-dose cytosine arabinoside Med Pediatr Oncol 11 246 50 10.1002/mpo.2950110408
14. MC Salinsky RL Levine JP Aubuchon HS Schutta 1983 Acute cerebellar dysfunction with high-dose ARA-C therapy Cancer 51 426 9 10.1002/1097- 0142(19830201)51:3<426::AID-CNCR2820510312>3.0.CO;2-S
15. MJ Barnett TS Ganesan JH Waxman MA Richards BF Smith AZ Rohatiner 1985 Neurotoxicity of high-dose cytosine arabinoside Prog Exp Tumor Res 29 177 88
16. MD Winkelman JD Hines 1983 Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study Ann Neurol 14 520 7 10.1002/ana.410140505
17. WK Yung TL Hwang J Martinez-Prieto YY Lee LG Feun 1985 Neurotoxicity of high-dose Ara-C and intracarotid chemotherapy Prog Exp Tumor Res 29 183 9
18. H Vogel DS Horoupian 1993 Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity Cancer 71 1303 8 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6
19. LA Dworkin RD Goldman LS Zivin PC Fuchs 1985 Cerebellar toxicity following high-dose cytosine arabinoside J Clin Oncol 3 613 6
20. MJ Barnett MA Richards TS Ganesan JH Waxman BF Smith MG Butler 1985 Central nervous system toxicity of high-dose cytosine arabinoside Semin Oncol 12 227 32
21. LE Damon R Mass CA Linker 1989 The association between high-dose cytarabine neurotoxicity and renal insufficiency J Clin Oncol 7 1563 8
22. GA Smith LE Damon HS Rugo CA Ries CA Linker 1997 High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency J Clin Oncol 15 833 9
23. H Hasle 1990 Cerebellar toxicity during cytarabine therapy associated with renal insufficiency Cancer Chemother Pharmacol 27 76 8 10.1007/BF00689281
24. TP Hardegger A von Rohr A Tobler MF Fey 1996 Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure Ann Hematol 72 327 8 10.1007/s002770050180
25. CS Chim YL Kwong 1996 Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency Am J Hematol 53 208 10.1002/(SICI)1096-8652(199611)53:3<208::AID-AJH17>3.0.CO;2-9
26. HM Jolson L Bosco MG Bufton BB Gerstman SS Rinsler E Williams 1992 Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine J Natl Cancer Inst 84 500 5 10.1093/jnci/84.7.500
27. LE Damon W Plunkett CA Linker 1991 Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-d-arabinofuranosylcytosine and 1-beta-d- arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-d-arabinofuranosylcytosine Cancer Res 51 4141 5
28. W Hiddemann E Schleyer C Uhrmeister CH Aul G Maschmeyer A Heinecke 1990 High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia-preliminary clinical and pharmacological data of a randomized comparison Cancer Treat Rev 17 279 85 10.1016/0305-7372(90)90058-N
29. E Schleyer G Ehninger M Zuhlsdorf B Proksch W Hiddemann 1989 Detection and separation of intracellular 1-beta-d-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography J Chromatogr A 497 109 20 10.1016/0378-4347(89)80010-6
30. Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G. Arzneimittelforschung. Model building in pharmacokinetics/Part III: simplified rules for the deduction of analytical solutions for linear compartment models (author's transl). 1977;27:904-11.
31. LM DeAngelis W Kreis K Chan E Dantis S Akerman 1992 Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside Cancer Chemother Pharmacol 29 173 7 10.1007/BF00686248
32. M Burk A Heyll M Arning M Volmer K Fartash W Schneider 1997 Pharmacokinetics of high-dose cytarabine and its deamination product-a reappraisal Leuk Lymphoma 27 321 7
33. RL Capizzi JL Yang E Cheng T Bjornsson D Sahasrabudhe RS Tan 1983 Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia J Clin Oncol 1 763 71
34. DH Ho E Frei 3rd 1971 Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine Clin Pharmacol Ther 12 944 54
35. SH Wan DH Huffman DL Azarnoff B Hoogstraten WE Larsen 1974 Pharmacokinetics of 1-beta-d-arabinofuranosylcytosine in humans Cancer Res 34 392 7
36. GP Jamieson MB Snook JS Wiley 1990 Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells Leuk Res 14 475 9 10.1016/0145-2126(90)90035-8
37. JC White JP Rathmell RL Capizzi 1987 Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells J Clin Invest 79 380 7 10.1172/JCI112823
38. FM Balis DG Poplack 1989 Central nervous system pharmacology of antileukemic drugs Am J Pediatr Hematol Oncol 11 74 86 10.1097/00043426- 198921000-00017
39. ML Slevin EM Piall GW Aherne A Johnston TA Lister 1982 The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy Med Pediatr Oncol 10 157 68 10.1002/mpo.2950100715
40. TL Wallace EM Johnson Jr 1989 Cytosine arabinoside kills postmitotic neurons: evidence that deoxycytidine may have a role in neuronal survival that is independent of DNA synthesis J Neurosci 9 115 24
41. JA Lopez RP Agarwal 1984 Acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside Cancer Treat Rep 68 1309 10